Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells

Published:2009-10 Issue:9 Volume:20 Page:832-837
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Ji Yuan,Ma Sheng-lin,Zhang Yi-ping,Tang Juan-juan,Wu Yan-ming,Lu Yan-Jun

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference30 articles.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003

2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;J Am Med Assoc,2003

3. Tumor necrosis factor, still a promising agent;Frei;J Clin Oncol,1989

4. A multicenter randomized phase II trial of domestic product of nrh-TNF in the treatment of non-small cell lung cancer;Zhou;Chin J Lung Cancer,2003

5. A clinical research on rnhTNF for 87 cases with advanced cancer;Chen;Chin J Clin Oncol,2003

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer;Frontiers in Oncology;2020-05-12

2. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer;Toxicology and Applied Pharmacology;2018-10

3. Up-Regulation of Transient Receptor Potential Melastatin 6 Channel Expression by Tumor Necrosis Factor-α in the Presence of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;Journal of Cellular Physiology;2017-04-25

4. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway;Current Cancer Drug Targets;2017-04-18

5. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1;Biomedicine & Pharmacotherapy;2017-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3